https://www.cancernetwork.com/view/adt-arpi-suspension-displays-feasibility-in-responders-with-metastatic-hspc2026-05-31T20:15:00Z2026-05-31T20:15:00Z https://www.cancernetwork.com/view/chemo-guided-by-ctdna-improves-outcomes-in-stage-ii-mss-colon-cancer2026-05-31T20:00:00Z2026-05-31T20:00:00Z https://www.cancernetwork.com/view/ascent-04-subgroup-analysis-yields-consistent-pfs-benefits-in-metastatic-tnbc2026-05-31T19:30:00Z2026-05-31T19:30:00Z https://www.cancernetwork.com/view/remote-mobile-health-intervention-triples-crc-surveillance-rates-in-childhood-cancer-survivors2026-05-31T19:00:00Z2026-05-31T19:00:00Z https://www.cancernetwork.com/view/daratumumab-combo-exhibits-sustained-efficacy-in-transplant-ineligible-ndmm2026-05-31T18:30:00Z2026-05-31T18:30:00Z https://www.cancernetwork.com/view/tocilizumab-supports-outpatient-bispecific-antibody-use-in-multiple-myeloma2026-05-31T18:00:00Z2026-05-31T18:00:00Z https://www.cancernetwork.com/view/adjuvant-atezolizumab-shows-minimal-impact-on-functioning-qol-in-mibc2026-05-31T17:54:40.587Z2026-05-31T17:54:40.587Z https://www.cancernetwork.com/view/adjuvant-aspirin-misses-dfs-stage-iii-crc2026-05-31T17:33:24.132Z2026-05-31T17:33:24.132Z https://www.cancernetwork.com/view/glp-1-receptor-agonists-may-improve-survival-reduce-iraes-in-ici-treated-patients2026-05-31T17:00:00Z2026-05-31T17:00:00Z https://www.cancernetwork.com/view/ctdna-dynamics-optimal-adjuvant-chemotherapy-duration-resected-crc2026-05-31T16:30:00Z2026-05-31T16:30:00Z https://www.cancernetwork.com/view/rp1-nivolumab-shows-os-benefit-in-anti-pd-1-progressed-melanoma2026-05-31T16:00:00Z2026-05-31T16:00:00Z https://www.cancernetwork.com/view/carboplatin-based-ic-ccrt-better-tolerated-vs-cisplatin-in-la-npc2026-05-31T15:45:36.115Z2026-05-31T15:45:36.115Z https://www.cancernetwork.com/view/nivolumab-tmc-i-reduces-risk-of-death-in-platinum-sensitive-hnscc2026-05-31T15:00:00Z2026-05-31T15:00:00Z https://www.cancernetwork.com/view/draxonrasib-shows-soc-potential-in-metastatic-pdac2026-05-31T14:16:15.255Z2026-05-31T14:16:15.255Z https://www.cancernetwork.com/view/efs-improves-with-selpercatinib-in-ret-nsclc-trial2026-05-31T14:09:59.039Z2026-05-31T14:09:59.039Z https://www.cancernetwork.com/view/sc-amivantamab-may-provide-more-convenience-in-chrysalis-2-regimen2026-05-31T14:00:00Z2026-05-31T14:00:00Z https://www.cancernetwork.com/view/personalized-cancer-vaccine-pembrolizumab-feasible-effective-newly-diagnosed-gbm2026-05-31T13:34:14.647Z2026-05-31T13:34:14.647Z https://www.cancernetwork.com/view/bezuclastinib-plus-sunitinib-meets-pfs-end-point-in-kit-mutant-gist2026-05-31T01:00:42.476Z2026-05-31T01:00:42.476Z https://www.cancernetwork.com/view/adjuvant-giredestrant-improves-invasive-dfs-er-her2-early-breast-cancer2026-05-30T23:44:06.578Z2026-05-30T23:44:06.578Z https://www.cancernetwork.com/view/azd3470-displays-clinical-activity-in-pretreated-classic-hodgkin-lymphoma2026-05-30T22:58:50.085Z2026-05-30T22:58:50.085Z https://www.cancernetwork.com/view/prosigna-guided-adjuvant-therapy-shows-noninferiority-in-er-her2-breast-cancer2026-05-30T20:19:47.269Z2026-05-30T20:19:47.269Z https://www.cancernetwork.com/view/rampart-trial-does-not-meet-dfs-end-point-in-rcc2026-05-30T20:00:00Z2026-05-30T20:00:00Z https://www.cancernetwork.com/view/teclistamab-monotherapy-improves-pfs-and-os-in-relapsed-refractory-myeloma2026-05-30T19:30:00Z2026-05-30T19:30:00Z https://www.cancernetwork.com/view/sequencing-adcs-in-breast-cancer-key-clinical-decision-markers2026-05-30T19:00:00Z2026-05-30T19:00:00Z https://www.cancernetwork.com/view/t-dxd-5-4-mg-kg-combos-yield-fewer-grade-3-aes-in-her2-gastric-cancers2026-05-30T18:15:00Z2026-05-30T18:15:00Z https://www.cancernetwork.com/view/mezigdomide-regimen-improves-pfs-in-pretreated-r-r-multiple-myeloma2026-05-30T18:00:00Z2026-05-30T18:00:00Z https://www.cancernetwork.com/view/tafasitamab-combo-prolongs-progression-vs-r-chop-alone-in-bcl-groups2026-05-30T16:30:00Z2026-05-30T16:30:00Z https://www.cancernetwork.com/view/enfortumab-vedotin-pembrolizumab-maintains-os-benefit-in-urothelial-carcinoma2026-05-30T16:00:00Z2026-05-30T16:00:00Z https://www.cancernetwork.com/view/deep-learning-tme-analysis-improves-prognostic-discrimination-in-stage-iii-colon-cancer2026-05-30T15:38:42.062Z2026-05-30T15:38:42.062Z https://www.cancernetwork.com/view/177lu-edotreotide-improves-hrqol-vs-everolimus-in-gep-nets2026-05-30T15:33:30.332Z2026-05-30T15:33:30.332Z https://www.cancernetwork.com/view/enfortumab-vedotin-pembrolizumab-shows-long-term-survival-benefit-in-1l-urothelial-carcinoma2026-05-30T14:00:00Z2026-05-30T14:00:00Z https://www.cancernetwork.com/view/omitting-alnd-non-inferiority-fewer-arm-related-complications-breast-cancer2026-05-30T13:23:59.112Z2026-05-30T13:23:59.112Z https://www.cancernetwork.com/view/relacorilant-maintains-os-benefit-in-ovarian-cancer-despite-prior-taxane-use2026-05-30T01:00:00Z2026-05-30T01:00:00Z https://www.cancernetwork.com/view/pembrolizumab-plus-chemotherapy-shows-sustained-survival-in-advanced-ec2026-05-30T00:28:59.849Z2026-05-30T00:28:59.849Z https://www.cancernetwork.com/view/higher-belantamab-mafodotin-dose-intensity-deepens-responses-in-transplant-ineligible-ndmm2026-05-29T23:33:30.845Z2026-05-29T23:33:30.845Z https://www.cancernetwork.com/view/amivantamab-regimen-boosts-survival-in-egfr-nsclc-subtype2026-05-29T23:00:00Z2026-05-29T23:00:00Z https://www.cancernetwork.com/view/six-nact-cycles-before-surgery-fail-to-improve-dfs-in-advanced-ovarian-cancer2026-05-29T22:36:25.580Z2026-05-29T22:36:25.580Z https://www.cancernetwork.com/view/sac-tmt-combo-improves-pfs-vs-pembrolizumab-in-nsclc2026-05-29T22:30:00Z2026-05-29T22:30:00Z https://www.cancernetwork.com/view/dostarlimab-yields-curative-potential-dmmr-msi-h-endometrial-cancer-ruby2026-05-29T22:04:54.408Z2026-05-29T22:04:54.408Z https://www.cancernetwork.com/view/elranatamab-shows-strong-efficacy-signal-in-smoldering-multiple-myeloma2026-05-29T22:00:00Z2026-05-29T22:00:00Z https://www.cancernetwork.com/view/asco-2026-key-genitourinary-oncology-trials-to-watch-for2026-05-29T16:30:00Z2026-05-29T16:30:00Z https://www.cancernetwork.com/view/fda-accepts-nda-grants-priority-review-bezuclastinib-sunitinib-pretreated-gist2026-05-29T15:05:57.172Z2026-05-29T15:05:57.172Z https://www.cancernetwork.com/view/can-structured-exercise-reprogram-the-tumor-microenvironment-in-oncology-2026-05-29T14:30:00Z2026-05-29T14:30:00Z https://www.cancernetwork.com/view/what-are-the-top-lymphoma-abstracts-at-asco-2026-2026-05-29T14:00:00Z2026-05-29T14:00:00Z https://www.cancernetwork.com/view/85-rwpcr-and-rwefs-in-early-stage-triple-negative-breast-cancer-patients-from-community-oncology-are-concordant-with-trial-end-point-estimates2026-05-28T22:30:00Z2026-05-28T22:30:00Z https://www.cancernetwork.com/view/86-gedatolisib-a-multitarget-pi3k-akt-mtor-pam-inhibitor-plus-fulvestrant-with-or-without-palbociclib-for-second-line-2l-treatment-of-patients-with-hr-her2-pik3ca-wild-type-wt-advanced-breast-cancer-abc-updated-results-from-viktoria-12026-05-28T22:00:00Z2026-05-28T22:00:00Z https://www.cancernetwork.com/view/asco-2026-the-presentations-that-may-shape-the-future-of-multiple-myeloma2026-05-28T20:00:00Z2026-05-28T20:00:00Z https://www.cancernetwork.com/view/prescribing-exercise-in-oncology-moving-beyond-good-luck-2026-05-28T18:00:00Z2026-05-28T18:00:00Z https://www.cancernetwork.com/view/how-the-landscape-gi-oncology-evolving-2026-asco-preview2026-05-28T17:30:00.697Z2026-05-28T17:30:00.697Z https://www.cancernetwork.com/view/durvalumab-plus-bcg-earns-fda-approval-for-high-risk-nmibc2026-05-28T16:45:30.837Z2026-05-28T16:45:30.837Z https://www.cancernetwork.com/view/aquablation-study-receives-ide-approval-in-low-grade-prostate-cancer2026-05-28T16:30:00Z2026-05-28T16:30:00Z https://www.cancernetwork.com/view/advancing-neuro-oncology-asco-know-before-you-go2026-05-28T16:00:00Z2026-05-28T16:00:00Z https://www.cancernetwork.com/view/neladalkib-earns-fda-priority-review-in-alk-positive-nsclc2026-05-28T15:30:00Z2026-05-28T15:30:00Z https://www.cancernetwork.com/view/the-moonlight-shift-maurie-markman-oncology-biggest-problems2026-05-28T15:00:00Z2026-05-28T15:00:00Z https://www.cancernetwork.com/view/moving-bispecific-antibodies-into-community-practice-operational-strategies-and-expert-consensus2026-05-28T14:00:00Z2026-05-28T14:00:00Z https://www.cancernetwork.com/view/this-week-in-breast-cancer-camizestrant-delay-bria-imt-data-recurrence-test2026-05-28T12:00:00Z2026-05-28T12:00:00Z https://www.cancernetwork.com/view/87-gedatolisib-a-multitarget-pi3k-akt-mtor-pam-inhibitor-plus-fulvestrant-with-or-without-palbociclib-for-second-line-2l-treatment-of-patients-with-hr-her2-pik3ca-wild-type-wt-advanced-breast-cancer-abc-topline-results-from-viktoria-12026-05-27T22:30:00Z2026-05-27T22:30:00Z https://www.cancernetwork.com/view/88-imlunestrant-with-or-without-abemaciclib-in-advanced-breast-cancer-abc-a-subgroup-analysis-in-cdk4-6-inhibitor-cdk4-6i--pretreated-patients-from-ember-32026-05-27T22:00:00Z2026-05-27T22:00:00Z https://www.cancernetwork.com/view/fda-approves-pivekimab-sunirine-in-rare-hematologic-malignancy2026-05-27T19:33:50.939Z2026-05-27T19:33:50.939Z https://www.cancernetwork.com/view/orelabrutinib-earns-australian-approval-in-relapsed-refractory-mcl2026-05-27T17:00:00Z2026-05-27T17:00:00Z https://www.cancernetwork.com/view/chmp-recommends-breakwater-regimen-for-approval-in-1l-braf-v600e-mcrc2026-05-27T15:30:00Z2026-05-27T15:30:00Z https://www.cancernetwork.com/view/toripalimab-regimen-improves-efs-mpr-rate-in-stage-ii-iii-nsclc-trial2026-05-27T15:00:00Z2026-05-27T15:00:00Z https://www.cancernetwork.com/view/anticipated-data-and-practice-changing-trials-an-asco-2026-breast-cancer-preview2026-05-27T14:00:00Z2026-05-27T14:00:00Z https://www.cancernetwork.com/view/ciltacabtagene-autoleucel-in-high-risk-smoldering-multiple-myeloma-the-car-prism-phase-2-trial2026-05-27T12:21:34.618Z2026-05-27T12:21:34.618Z https://www.cancernetwork.com/view/gvhd-prophylaxis-after-cord-blood-transplantation-in-patients-with-high-risk-aml-a-nationwide-japanese-cohort-study2026-05-27T12:17:40.992Z2026-05-27T12:17:40.992Z https://www.cancernetwork.com/view/why-do-cns-malignancies-matter-in-radiation-oncology-2026-05-27T12:00:00Z2026-05-27T12:00:00Z https://www.cancernetwork.com/view/89-imlunestrant-with-or-without-abemaciclib-as-first--and-second-line-therapy-in-advanced-breast-cancer-abc-a-subgroup-analysis-from-the-ember-3-trial2026-05-26T22:30:00Z2026-05-26T22:30:00Z https://www.cancernetwork.com/view/90-real-world-esr1-mutation-and-testing-rates-in-patients-with-er-her2-metastatic-breast-cancer2026-05-26T22:00:00Z2026-05-26T22:00:00Z https://www.cancernetwork.com/view/exercise-regimens-could-disrupt-accelerated-cellular-aging-in-cancer2026-05-26T18:00:00Z2026-05-26T18:00:00Z https://www.cancernetwork.com/view/concomitant-covid-19-vaccination-improved-os-immunotherapy2026-05-26T15:23:25.175Z2026-05-26T15:23:25.175Z https://www.cancernetwork.com/view/fda-approves-foundationone-cdx-for-tepotinib-in-met-nsclc2026-05-26T14:30:00Z2026-05-26T14:30:00Z https://www.cancernetwork.com/view/optimizing-the-treatment-experience-cocoon-counseling-and-anticoagulation2026-05-12T12:05:00.000Z2026-05-26T12:05:00Z https://www.cancernetwork.com/view/navigating-car-t-cell-therapy-use-as-a-team-sport-in-multiple-myeloma2026-05-26T12:00:00Z2026-05-26T12:00:00Z https://www.cancernetwork.com/view/safety-tolerability-and-the-ae-profile-of-sc-q4w-in-cohort-52026-05-12T12:05:00.000Z2026-05-26T12:00:00Z https://www.cancernetwork.com/view/91-real-world-survival-outcomes-by-risk-features-in-patients-with-hr-her2-early-breast-cancer-in-the-united-states2026-05-25T22:30:00Z2026-05-25T22:30:00Z https://www.cancernetwork.com/view/92-abemaciclib-after-abemaciclib-a-real-world-comparative-analysis-challenging-the-paradigm-of-sequential-cdk4-6-inhibitors-in-metastatic-breast-cancer2026-05-25T22:00:00Z2026-05-25T22:00:00Z https://www.cancernetwork.com/view/navigating-the-dynamic-landscape-of-stem-cell-transplantation2026-05-25T12:00:00Z2026-05-25T12:00:00Z https://www.cancernetwork.com/view/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2-high-risk-early-breast-cancer2026-05-24T22:30:00Z2026-05-24T22:30:00Z https://www.cancernetwork.com/view/94-treatment-persistence-and-dose-modifications-in-us-patients-with-hr-her2-node-positive-early-breast-cancer-treated-with-adjuvant-abemaciclib2026-05-24T22:00:00Z2026-05-24T22:00:00Z https://www.cancernetwork.com/view/outlining-exercise-as-a-biologically-interventional-therapy-for-cancer2026-05-24T14:00:00Z2026-05-24T14:00:00Z https://www.cancernetwork.com/view/95-monarche-subgroup-analysis-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2-high-risk-early-breast-cancer-by-nodal-status2026-05-23T22:30:00Z2026-05-23T22:30:00Z https://www.cancernetwork.com/view/96-efficacy-and-safety-of-abemaciclib-in-younger-patients-with-early-breast-cancer-in-the-monarche-trial2026-05-23T22:00:00Z2026-05-23T22:00:00Z https://www.cancernetwork.com/view/quizartinib-regimen-appears-effective-in-flt3-itd-aml-trial2026-05-23T14:00:00Z2026-05-23T14:00:00Z https://www.cancernetwork.com/view/97-monarche-evaluation-of-prognostic-and-predictive-value-of-ki-67-index-pre--and-post-neoadjuvant-chemotherapy-and-changes-following-nac2026-05-22T22:30:00Z2026-05-22T22:30:00Z https://www.cancernetwork.com/view/98-a-phase-1-2-trial-of-ly4064809-a-pan-mutant-selective-pi3k-inhibitor-in-hr-her2-advanced-breast-cancer-updated-results-from-pikalo-12026-05-22T22:00:00Z2026-05-22T22:00:00Z https://www.cancernetwork.com/view/fda-oks-guardant360-liquid-cdx-expanded-molecular-profiling2026-05-22T16:52:16.184Z2026-05-22T16:52:16.184Z https://www.cancernetwork.com/view/chmp-gives-positive-opinion-for-pembrolizumab-containing-combo-in-mibc-type2026-05-22T16:30:00Z2026-05-22T16:30:00Z https://www.cancernetwork.com/view/sacituzumab-tirumotecan-meets-pfs-end-point-as-1l-option-in-advanced-tnbc2026-05-22T15:30:00Z2026-05-22T15:30:00Z https://www.cancernetwork.com/view/fda-approves-dato-dxd-for-metastatic-triple-negative-breast-cancer2026-05-22T14:29:41.817Z2026-05-22T14:29:41.817Z https://www.cancernetwork.com/view/99-imlunestrant-with-or-without-abemaciclib-in-advanced-breast-cancer-updated-efficacy-results-from-the-phase-3-ember-3-trial2026-05-21T22:30:00Z2026-05-21T22:30:00Z https://www.cancernetwork.com/view/100-imlunestrant-plus-abemaciclib-versus-fulvestrant-plus-abemaciclib-in-estrogen-receptor-positive-er-human-epidermal-growth-factor-receptor-2-negative-her2-advanced-breast-cancer-abc-an-indirect-treatment-comparison-itc-of-three-phase-3-trials2026-05-21T22:00:00Z2026-05-21T22:00:00Z https://www.cancernetwork.com/view/data-readouts-to-watch-at-the-2026-asco-annual-meeting2026-05-21T21:48:04.156Z2026-05-21T21:48:04.156Z https://www.cancernetwork.com/view/telephone-based-weight-loss-program-improves-physical-function-qol-in-breast-cancer2026-05-21T21:22:11.780Z2026-05-21T21:22:11.780Z https://www.cancernetwork.com/view/arteraai-pathology-test-launches-for-personalizing-prostate-cancer-therapy2026-05-21T20:00:00Z2026-05-21T20:00:00Z https://www.cancernetwork.com/view/discussing-chemo-trends-and-end-point-selection-in-older-patients-with-tnbc2026-05-21T18:00:00Z2026-05-21T18:00:00Z https://www.cancernetwork.com/view/osteosarcoma-drug-earns-rare-pediatric-disease-orphan-drug-designations2026-05-21T15:59:08.182Z2026-05-21T15:59:08.182Z https://www.cancernetwork.com/view/alpha-dart-elicits-100-local-disease-control-in-pancreatic-cancer2026-05-21T14:00:00Z2026-05-21T14:00:00Z https://www.cancernetwork.com/view/101-patient-reported-outcomes-pros-in-patients-with-er-her2--advanced-breast-cancer-abc-treated-with-imlunestrant-investigator-s-choice-standard-endocrine-therapy-or-imlunestrant-abemaciclib-results-from-the-phase-iii-ember-3-trial2026-05-20T22:30:00Z2026-05-20T22:30:00Z https://www.cancernetwork.com/view/102-imlunestrant-imlu-with-or-without-abemaciclib-abema-in-advanced-breast-cancer-abc-safety-analyses-from-the-phase-iii-ember-3-trial2026-05-20T22:00:00Z2026-05-20T22:00:00Z https://www.cancernetwork.com/view/alpha-dart-overcomes-anatomical-constraints-in-inoperable-pancreatic-cancer2026-05-20T19:00:00Z2026-05-20T19:00:00Z